A consistent infusion schedule with chemotherapy-free post-induction dosing
Infusions once every 3 weeks 1,4
- TECENTRIQ should be administered prior to bevacizumab, paclitaxel, and carboplatin on Day 1 of each cycle
- Administer the initial infusion of TECENTRIQ over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes
- Do not administer TECENTRIQ as an IV push or bolus
- Do not co-administer other drugs through the same IV line
- Refer to the respective Prescribing Informations for bevacizumab, paclitaxel, and carboplatin for recommended dosing information
1L=first line; AUC=area under the
concentration-time curve; IV=intravenous; NSCLC=non-small cell lung
Based on dosing schedule from IMpower150.
*In patients of Asian race/ethnicity, the paclitaxel dose was lowered from 200 mg/m2 to 175 mg/m2.
Dosage modifications from the TECENTRIQ Prescribing Information 1
No dose reductions of TECENTRIQ are recommended.
|Adverse reaction||Severity of adverse reaction†||Dosage modifications|
|Pneumonitis||Grade 2||Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)|
|Grade 3 or 4||Permanently discontinue|
|Hepatitis||AST or ALT >3 and ≤8 times
ULN or total bilirubin >1.5 and ≤3 times ULN
||Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)|
|AST or ALT >8 times ULN or total bilirubin >3 times
ULN ||Permanently discontinue |
|Colitis or diarrhea||Grade 2 or 3 ||Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)|
|Grade 4 ||Permanently discontinue |
|Endocrinopathies‡||Grade 2, 3, or 4 ||Withhold dose until grade 1 or resolved and clinically
stable on hormone replacement therapy |
|Other immune-mediated adverse reactions involving a major organ||Grade 3|
|Grade 4||Permanently discontinue |
|Infections||Grade 3 or 4||Withhold dose until
grade 1 or resolved |
|Infusion-related reactions||Grade 1 or 2||Interrupt or slow the rate of infusion |
|Grade 3 or 4||Permanently discontinue |
|Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies)||Grade 2 or 3 adverse reaction that does
not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ
dose ||Permanently discontinue |
|Inability to taper corticosteroid||Inability to reduce
to less than or equal to prednisone 10 mg per day (or
equivalent) within 12 weeks after last TECENTRIQ dose ||Permanently discontinue |
|Recurrent grade 3 or 4 adverse reactions||Recurrent
grade 3 or 4 (severe or life-threatening) adverse
reactions ||Permanently discontinue |
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.
†Graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
‡Including, but not limited to hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.